poisar

Stocks · News reference

When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges

Vandana Singh

SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RVMDSLS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Prosper Junior Bakiny

    Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?

    Revolution Medicines received FDA approval for Rasonque, an innovative pancreatic cancer treatment that beat chemotherapy in clinical trials. Billionaire Stanley Druckenmiller's Duquesne Family Office increased its stake by 26.5% in Q2. While the stock has surged 134% and currently trades at a $40B market cap, the analyst suggests waiting for a $5B market cap reduction before buying, citing the need for a better margin of safety in the volatile biotech sector.

    RVMDRVMDW
  3. Delveinsight

    Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight

    The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.

    JNJEXELABBVAGENVSTM